Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
665.6 INR | -5.13% | +2.56% | +21.97% |
Apr. 17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Feb. 02 | India's Jubilant Pharmova posts quarterly profit | RE |
Sales 2022 | 61.3B 736M | Sales 2023 | 62.82B 754M | Capitalization | 44.42B 533M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.67M | Net income 2023 | -610M -7.32M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | -5.13% | ||
1 week | +2.56% | ||
Current month | +17.09% | ||
1 month | +16.75% | ||
3 months | +19.98% | ||
6 months | +62.73% | ||
Current year | +21.97% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +1.25% | - | |
0.00% | 117 M€ | -1.55% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 665.6 | -5.13% | 67,295 |
24-04-18 | 701.6 | +4.47% | 93,784 |
24-04-16 | 671.6 | +3.31% | 41,584 |
24-04-15 | 650.1 | +1.73% | 52,689 |
24-04-12 | 639 | -1.54% | 13,584 |
Delayed Quote Bombay S.E., April 19, 2024 at 06:21 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+21.97% | 1.34B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- JUBLPHARMA Stock